This content is locked down to the Global Reveal 2022: Investor Portal demo day. Click here to access the content via the demo day.

Neuro-stimulation is a revolution in medicine that could transform 200 million lives. For example, Deep Brain Stimulation (DBS) is a quality of life surgery in Parkinson’s disease. However, only a handful of people with movement disorders benefit from this therapy because the manual programming is a tedious trial-and-error process over several months and no tool is able to predict the clinical outcome; this prevents much broader applications in psychiatry (depression, OCD, eating disorders) and dementia (Alzheimer’s disease). 

47 Lab unlocks brain therapy for all. The company develops solutions for better planning of  medical interventions and automated optimization of device settings to achieve the best clinical outcome, while preventing side effects within a single day. This technology is a paradigm shift based on an academic tool with over 10 years of development and 500 scientific publications.